Executive interview – Interpace Diagnostics

Published on 24 June 2019
 

In this interview, Jack Stover, chief executive officer of Interpace Diagnostics Group, discusses some of the opportunities and challenges in the diagnostics space and provides an overview of how the group is uniquely situated with a differentiated product service offering and significant milestones ahead.

Interpace Diagnostics Group (IDXG:US) is a fully integrated commercial and bioinformatics company that provides evidence-based, clinically beneficial molecular diagnostic tests and pathology services. The company develops and commercializes molecular diagnostic tests that deliver cutting-edge genetic and mutational analysis. The tests help risk-stratify patient samples for thyroid, pancreatic, lung and other cancers to better inform treatment decisions.

This interview contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to Interpace Diagnostics’ (the Company’s) future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. Additionally, all forward-looking statements are subject to the risk factors detailed from time to time in the Company’s filings with the SEC, including without limitation, the 2018 Annual Report on Form 10-K filed with the SEC and the Company’s Quarterly Reports on Form 10-Q. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this interview and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Share this with friends and colleagues